Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 2,100

Hikma Pharmaceuticals (LON:HIK) had its target price hoisted by Berenberg Bank from GBX 1,800 to GBX 2,100 in a research report report published on Tuesday morning,Digital Look reports. Berenberg Bank currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on HIK. Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Jefferies Financial Group raised their price target on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of GBX 2,060.

Hikma Pharmaceuticals Trading Down 0.2%

Hikma Pharmaceuticals stock opened at GBX 1,643 on Tuesday. The company has a market capitalization of £3.43 billion, a price-to-earnings ratio of 9.08, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The business’s fifty day simple moving average is GBX 1,551.07 and its two-hundred day simple moving average is GBX 1,455.57. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Insiders Place Their Bets

In other news, insider Tobias Hestler bought 7,500 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average cost of GBX 1,648 per share, with a total value of £123,600. Corporate insiders own 22.04% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.